(Q45413779)

English

Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses

scientific article published on 12 July 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

vector-borne disease

0 references

8

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Roberto Manservigi

object named as

Roberto Manservigi

6

0 references

Antonella Caputo

object named as

Antonella Caputo

5

0 references

object named as

Barbara Ensoli

7

0 references

author name string

Aleksandra Bozac

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Elena Berto

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Federica Vasquez

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Paola Grandi

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

12 July 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

49-50

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

7148-7158

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Future vaccines: recent advances and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

The past, present and future of HIV-vaccine development: a critical view.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Clinical trials of HIV vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Memory T cells and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Rev activity determines sensitivity of HIV-1-infected primary T cells to CTL killing.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Catastrophes after crossing species barriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Vaccination with Rev and Tat against AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

HIV-1 Tat-based vaccines: from basic science to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

A novel chimeric Rev, Tat, and Nef (Retanef) antigen as a component of an SIV/HIV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Gene combination raises broad human immunodeficiency virus-specific cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Vaccine development against HIV-1: current perspectives and future directions.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

A new generation of HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Virus-based vectors for human vaccine applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Live Recombinant Vectors for AIDS Vaccine Development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Development of a DNA-MVA/HIVA vaccine for Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Alphavirus replicon particles as candidate HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Insertion of HIV-1 Genes into Ad4ΔE3 Vector Abrogates Increased Pathogenesis in Cotton Rats Due to E3 Deletion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

A retroviral DNA vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Expression of the human immunodeficiency virus gag gene products by a replication-incompetent herpes simplex virus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Evaluation in Rhesus Macaques of Tat and Rev-Targeted Immunization as a Preventive Vaccine against Mucosal Challenge with SHIV-BX08

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Replication-defective herpes simplex virus vectors for gene transfer in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Synthesis of the complete trans-activation gene product of human T-lymphotropic virus type III in Escherichia coli: demonstration of immunogenicity in vivo and expression in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Three novel genes of human T-lymphotropic virus type III: immune reactivity of their products with sera from acquired immune deficiency syndrome patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Rapid method for construction of recombinant HSV gene transfer vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

A sensitive promoter assay based on the transcriptional activator Tat of the HIV-1 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

A quantitative assay for trans-activation by HIV-1 Tat, using liposome-mediated DNA uptake and a parallel ELISA system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Identification of a peptide capable of inducing an HIV-1 Tat-specific CTL response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant ΔV2 Env

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Deletion of the virion host shutoff protein (vhs) from herpes simplex virus (HSV) relieves the viral block to dendritic cell activation: potential of vhs- HSV vectors for dendritic cell-mediated immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Nucleic acid vaccination with HIV regulatory genes: a combination of HIV-1 genes in separate plasmids induces strong immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

DNA vaccination in mice using HIV-1 nef, rev and tat genes in self-replicating pBN-vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Recent advances in the development of HIV-1 Tat-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

A call for replicating vector prime-protein boost strategies in HIV vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Replication-defective viruses as vaccines and vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.061

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.06.061

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45413779&oldid=2076854829"